This article discusses modern approaches to inhalation therapy for bronchial asthma and chronic obstructive pulmonary disease, with particular emphasis on the choice of drug delivery devices. Special attention is given to strategies for selecting inhalers and their impact on treatment effectiveness. Patient characteristics and dosage forms to be considered when prescribing inhalation therapy are reviewed.
Interim results of an observational clinical study evaluating the efficacy and safety of Asmalib® Air (ciclesonide 160 μg) in 35 adult patients with mild uncontrolled bronchial asthma are presented.
Improvements in asthma control parameters were observed: the mean increase in forced expiratory volume (1st second) was 7.5% (p < 0.0001), and ACT (Astma Control Test) scores increased from 17.03 to 21.07 points. A subanalysis in smoking patients also demonstrated a positive effect of extrafine ciclesonide.
According to preliminary results obtained in a real-world clinical setting, Asmalib® Air (ciclesonide 160 μg) is an effective and safe option for maintenance therapy of mild bronchial asthma. Further studies are required to confirm these findings and assess long-term efficacy and safety.
M.Yu. Peredelskaya
Russian Medical Academy of Continuing Professional Education, Ministry of Health of the Russian Federation, Moscow, City Clinical Hospital No. 24, Moscow Healthcare Department, Moscow
O.V. Sebekina
Russian Medical Academy of Continuing Professional Education, Ministry of Health of the Russian Federation, Moscow, City Clinical Hospital No. 24, Moscow Healthcare Department, Moscow
A.A. Yudin
City Clinical Hospital No. 24, Moscow Healthcare Department, Moscow, Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation, Moscow
I.A. Vasilyeva
City Hospital No. 40 of the Kurortny District, Saint Petersburg, “Energy of Health” (Energiya Zdorovya) Clinic, Saint Petersburg, “Blagodatnaya” Clinic, Saint Petersburg
Yu.E. Kizhaev
Professor Y.N. Kasatkin Clinic, Russian Medical Academy of Continuing Professional Education, Ministry of Health of the Russian Federation, Moscow
I.A. Bykov
Russian Medical Academy of Continuing Professional Education, Ministry of Health of the Russian Federation, Moscow
N.M. Nenasheva
Russian Medical Academy of Continuing Professional Education, Ministry of Health of the Russian Federation, Moscow
2 Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2025 Available at:
https://ginasthma.org/wp-content/uploads/2025/07/GI-NA-2025-Strategy-Report_25_05_25-WMS-2.pdf
3 Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2025 Report. 2025 Available at: https://goldcopd.org/2025-gold-report/#
4 Laube B.L., Janssens H.M., de Jongh F.H. et al.; European Respiratory Society; International Society for Aerosols in Medicine. What the pulmonary specialist should know about the new inhalation therapies. Eur. Respir. J. 2011; 37 (6): 1308–1331.
5 Chrystyn H., van der Palen J., Sharma R. et al. Device er-rors in asthma and COPD: systematic literature review and meta-analysis. NPJ Prim. Care Respir. Med. 2017; 27 (1):22
6 Kocks J.W.H., Chrystyn H., van der Palen J. et al. Systema-tic review of association between critical errors in inhala-tion and health outcomes in asthma and COPD. NPJ Prim. Care Respir. Med. 2018; 28 (1): 43
7 Molimard M., Raherison C., Lignot S. et al. Assessment of handling of inhaler devices in real life: an observatio-nal study in 3811 patients in primary care. J. Aerosol Med.2003; 16 (3): 249–254.
8 Scullion J. The nurse practitioners’ perspective on inhaler education in asthma and chronic obstructive pulmonary disease. Can. Respir. J. 2018; 2018: 2525319
9 Cataldo D., Hanon S., Peché R.V. et al. How to choose the right inhaler using a patient-centric approach? Adv. Ther. 2022; 39 (3): 1149–1163.
10 Barbara S., Kritikos V., Bosnic-Anticevich S. Inhaler tech-nique: does age matter? A systematic review. Eur. Respir. Rev. 2017; 26 (146): 170055